Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moreover, LP made it a point to say how refreshingly cooperative the MHRA was to approve the PIP in nearly half the standard time. That's a pretty strong signal or a read between the lines kind of statement IMHO.
Griffin purchased St. Tropez mansion just before buying dinosaur https://www.chicagobusiness.com/finance-banking/ken-griffin-bought-st-tropez-home-buying-stegosaurus
$20 million dollar fraud suit seems like a sacrificial lamb to appease the regulatory criticism. I don't agree with the bottom up, but rather a top down approach. The rationale is quite obvious.
Defendants had tried to use holiday and vacation time away as an excuse to lengthen the amended filing deadlines, but the Judge opted for a tighter schedule. I don't see why the Judge wouldn't apply the same standard for the court's decision.
Guzzi62 and dstock, you two are good people. Emotions run high. I'll go on a limb and say, dstock was irritated with Femke and his choice of words wasn't a judgement in general. As for Guzz, I understood what you meant. I put Nemesis on ignore a long time ago.
Let's move on 😉😎💪
Roman and others more knowing can correct me if I'm off base, but it seems to me, from Eden's small footprint and closed loop minimalist design, that validation could happen in short order. I would imagine that the commercial units will ship ready for showtime. We're not talking about an airline jet engine here.
WOW, two whole years younger 🤯 Remarkable!
BTW - Recently watched, think he was no more than 12 years old, beat Grand Master Magnus Carlson in 38 seconds.
Gus1212 - 😁 It wouldn't be the first time I dropped a bomb here, and you know, anything that has a hint of OT gets deleted. In any case, unlike some of the other things, this subject matter wouldn't make sense to explain in isolation. Like NWBO, at some point, everything comes to light.
There's a lot there to unpack. I'll leave it there.
The Flashworks update has reinforced NWBO'S superiority in the DC Space. With the recent Roswell deal in place, NWBO has the goods to pursue more DC based deals with it's market advantage, if, and when other DC based research appears promising, either to secure commercial rights, or have early productive discussions around that potential.
Also something to think about since we're discussing NWBO's strategy to see itself as a one stop shop for DC based technology. We recently learned about some very early research using CRISPER and DC's. Assuming that the method has some promise, since it was introduced that way in a recent funding announcement, I wouldn't be surprised if LP placed a call to that institution. It's never to early to start a discussion.
beartrap - You are correct. Administration pathways are generic. NWBO owns the commercial rights for any DC trial success conducted by Roswell. In an earlier ASM, LP mentioned that BP had not shown a willingness to contribute resources towards a combo trial. Perhaps she meant a specific BP like Merck or BMY. It's interesting to note the timing of this Merck/Roswell combo trial because it's fairly recent. I bet Merck was blindsided by NWBO's recent announcement of an agreement with Roswell that gives NWBO commercial control of Roswell 's DC's. 😃
He bought the IP of a small biotech, which wasn't proven successful. He rebranded it, used his Mom's bogus research paper to claim effecacy. He used his wall street buddies to hype the stock, which caused the stock to skyrocket. By the time the market understood that the drug offered no benefit, he had already dumped his entire position at peak, and it crashed soon afterwards.
Very interesting, but boy, am I not surprised: From the RICO suit -
Defendants Citadel, Peter Thiel, Vivek Ramaswamy
dstock - I understand the nature of your viewpoint. Nonetheless, I know from licensing in general, you wouldn't expect to see the kind of multiple in a licensing deal, as you would in a BO. Billions would in return demand an exclusive of some sort. Or a fraction of the royalties for each sale. I'm not one to speculate over and beyond what I know, or see trending to gauge direction. Just like I don't try to guess, or project when the approval happens. I understand it has its place for some, but for me, I keep my expectations tempered, and leave room for pleasant surprises, and less opportunity for disappointment. Great progress of late. That's awesome.
Foogie - Thanks for sharing that remarkably enlightening post. Everyone should read it, and more than once to make sure its gravity is fully appreciated. 🚀🔥📢🎯💯🏆💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰
That's correct. In a joint development, both sides take risk by committing their respective R&D resources. That entitles both sides to an equal share of the potential profits. In a licensing deal, NWBO is not taking the risk. Just collecting royalties. Merck takes on the risk for promoting, managing, and selling the combination treatment.
dstock - That's a joint development deal. That's much different than a licensing deal.
Was that deal for licensing? I forget.
stock - Should be a no-brainer for Merck to licence dcvax, since NWBO holds the combo patent. Who did NWBO have in mind when applying for the combo patent? After all, NWBO is not in the CI business. Certainly, serious discussions for a Partnership would not have advanced further, before the issuance of the patents NWBO only recently gained approval for. $1 billion upfront is not a big ask for what Merck stands to benefit by extending it's Keytruda franchise.
Check out @archetypal message on Stocktwits http://stocktwits.com/archetypal/message/580613175
The article referenced by the Stocktwits poster shows a photo of Robert David Steele, who I used to follow four years ago. He's a former high ranking intelligence officer turned crusader, which ultimately cost him his job. He's talked about naked shorting for years, among other illicit trades. Wall Street has stolen $100 trillion through naked shorting according to him.
IDK, but it appears as if there's an acceleration of suits filed against Citadel et al with today's news of the RICO suit. Imagine how huge the number of victims are, who never had their day to challenge these thieves in court. I just don't see that kind of subterfuge on a massive scale without the encouragement of unchecked protections in place. I hope the furry of suits we're seeing is a sign that suggests those protective forces themselves have been compromised to the extent, that may explain why things are happening now, when they weren't before.
What are you the town cryer?
The COVID vaccine space is an inappropriate comparison, but I would agree with you, that foul play could have played a roll in the fate of NXRP. It's a Pandora's box that is not worth expanding here. For anyone interested, there's a lot of disturbing criminal history behind the CDC. Censored yes, but it's available and overwhelming. I'll leave it there. DCVAX is not in that infectious disease space.
It's the other way around. A revolutionary threat, if a rejection is the method of choice to squash it, then it should have been rejected far earlier than at this stage. However, I can see slow walking the process, so that the sellers of snake oil could squeeze every drop of profit until that something else comes along.
He's right, and it was in this life time. Maybe not for an extended period, but it was.
No comment. 🤔
Boiler plate is typically 500,000. NWBO was 1.7 million.
Moreover, DCs must be out of Vogue, because it's old news right?But for some reason, there's a flurry of active research on DCs. Funny how that happens.
You're right, 1.7 million pages of data is pretty nuts for the hacks at the RA's to handle to begin with, just as it is, obviously, for an alleged IT hack, desperately thinking he's more relevant than LL et al. Now that's crazy. I recommend purchasing a mirror, if you don't have one, maybe the reflection may offer some help.
Interim looks into trials allow regulators to stop futile treatments from advancing further at the expense of patients who deserve to receive the best options. The RA's are consulted over time, when, or if the futility signal isn't seen earlier in the trial. It was at the behest of the RAs to crossover, while accruing 5 year data to see the formation of a fat tail. There is no other company that has as much data in its possession, and over as many years as NWBO has. In sum, two decades has allowed NWBO to pioneer new knowledge, and frankly, RA's need to rely upon such knowledge, just to keep up with the science. It's a different story unfortunately with BPs. There are two many examples to sight here, where BPs have been caught RED handed, something that is never part of the arguments coming from the shills, using corrupt practices like fraudulent trial data, filling FDA advisory boards with their their own people, among other shenanigans However, NWBO's meticulous research practices, which are unquestionably, 1st rate, and coming from the most prestigious institutions, conducted by the most prestigious experts in their fields, leaves nothing for RA's to second guess. If perfection was the standard, as it appears from some unlearned claims, we wouldn't have a Century of Chemorad to show for progress would we?
So by that logic LP ought to enjoy the same access, but nepotism is an unearned club to play in.
Everyone? 🤔
MartyDg - You must have inside knowledge to be so definitive. Please share.
Manibio - But LP didn't have a sugar daddy Gov't pampering him either. Respectfully, I think you have a very naive concept of what it takes to accomplish what NWBO has. The most ardent critics here have never launched a small biotech.
Cofer Black would have known if the MHRA had not intended to approve.
Tax payer subsidies I classify as public money.